Daily Physiotherapy Extended Ambulatory Function by 4.6x — but the Clock Is Always Running
Degenerative myelopathy (DM) is progressive, incurable, and universally fatal. It begins with subtle hindlimb weakness — often mistaken for arthritis or hip dysplasia — and progresses relentlessly to complete paraplegia, forelimb involvement, and eventually respiratory failure. Most affected dogs are euthanized within 6 to 36 months of symptom onset.
What makes DM scientifically remarkable is the 2009 discovery by Awano et al. that it is caused by a mutation in the SOD1 gene — the same gene mutated in a subset of human amyotrophic lateral sclerosis (ALS). Published in the Proceedings of the National Academy of Sciences, this finding established DM as a true canine homolog of ALS, sharing not only the genetic basis but the pathological features: progressive axonal degeneration, demyelination, and motor neuron loss in the spinal cord.
Genetics
The SOD1:c.118G>A missense mutation follows autosomal recessive inheritance with incomplete penetrance. Dogs must carry two copies of the mutation (homozygous) to be at risk, but not all homozygous dogs develop clinical disease.
Age-dependent penetrance means dogs must live long enough for the disease to manifest — estimated onset is typically 8 years or older. Some homozygous dogs die of other causes before DM ever develops.
Zeng et al. (2014) documented the breed distribution of the SOD1 mutation across over 30,000 dogs tested. Key findings:
- German Shepherds: The breed in which DM was first characterized. Carrier rates of 25-35% and homozygous (at-risk) rates of 2-5%.
- Pembroke Welsh Corgis: Among the highest at-risk breed populations, with homozygous rates exceeding 10% in some lines.
- Boxers: Carry the SOD1 mutation at moderate frequency. A second SOD1 variant (SOD1:c.52A>T) has been identified in Bernese Mountain Dogs and may contribute to DM risk in that breed.
- Rhodesian Ridgebacks, Chesapeake Bay Retrievers, and Cardigan Welsh Corgis: Also carry the mutation at clinically significant rates.
The incomplete penetrance creates a diagnostic challenge: a positive genetic test confirms risk but does not guarantee disease development. Conversely, a negative test (homozygous normal) effectively rules out SOD1-associated DM.
Clinical Stages
Coates and Wininger (2010) described a four-stage clinical progression:
Stage 1: Upper Motor Neuron Hindlimb Paresis (6-12 months)
The earliest signs are subtle and often attributed to arthritis or hip dysplasia. Owners notice scuffing of the rear paw nails (wearing on the dorsal surface), a slightly wobbly gait, and difficulty rising from a lying position.
The dog crosses the rear limbs while walking and may swing the rear end when turning. Proprioceptive deficits — delayed or absent conscious correction when the paw is placed knuckled-over — are the earliest clinical finding on neurological examination.
Importantly, DM is not painful. Unlike intervertebral disc disease, which causes acute pain and sudden-onset paralysis, DM produces gradual, painless loss of function. Dogs remain alert, engaged, and apparently comfortable throughout most of the disease course.
Stage 2: Lower Motor Neuron Hindlimb Paraplegia (3-6 months)
Rear limb weakness progresses to complete inability to support weight on the hind legs. The dog becomes non-ambulatory in the rear and begins dragging the hindquarters. Muscle atrophy becomes severe. Urinary and fecal incontinence may develop as lower motor neurons controlling bladder and bowel function are affected.
Stage 3: Forelimb Involvement (1-3 months)
The degenerative process ascends the spinal cord to affect the cervical segments, causing forelimb weakness and incoordination. Dogs in this stage become quadriparetic — unable to walk on any limb. Swallowing difficulty and respiratory compromise may develop as brainstem motor neurons become involved.
Stage 4: Respiratory Failure
Involvement of the intercostal motor neurons and phrenic nerve leads to respiratory muscle weakness and, ultimately, respiratory failure. Most dogs are euthanized before reaching this stage due to profound disability.
Diagnosis
DM remains a diagnosis of exclusion during life. The definitive diagnosis requires post-mortem histopathological examination of the spinal cord showing characteristic degenerative changes — axonal degeneration and demyelination in all funiculi (white matter columns) of the thoracolumbar spinal cord.
The clinical diagnostic approach combines:
- Compatible signalment: Breed at risk, age over 8 years
- Compatible neurological examination: Progressive, non-painful upper motor neuron paraparesis with proprioceptive deficits
- SOD1 genetic testing: Homozygous mutant status (necessary but not sufficient)
- MRI of the thoracolumbar spine: To rule out compressive myelopathy (intervertebral disc disease, spinal tumors). DM produces no visible compressive lesion on MRI.
- Cerebrospinal fluid analysis: Typically normal in DM. Elevated protein or pleocytosis suggests an inflammatory or infectious myelopathy.
The challenge is that many dogs have concurrent conditions — hip dysplasia, lumbosacral disease, osteoarthritis — that produce overlapping clinical signs. A dog with confirmed SOD1 homozygosity, compatible examination findings, normal spinal MRI, and progressive decline has a high clinical probability of DM, but certainty requires histopathology.
Physical Rehabilitation
Kathmann et al. (2006) published the strongest evidence for any intervention in canine DM. Dogs receiving intensive daily physiotherapy — a structured program of walking, supported exercises, and hydrotherapy — maintained ambulatory function for a median of 255 days. Dogs with moderate exercise programs lasted 130 days. Dogs with no physiotherapy: 55 days.
Physiotherapy does not alter the underlying neurodegenerative process. What it does is preserve functional capacity by maintaining muscle mass, cardiovascular fitness, and neural compensation mechanisms for longer than sedentary management allows. The implication is clear: aggressive physical rehabilitation should begin as soon as DM is suspected, not delayed until significant function is lost.
Effective rehabilitation strategies include:
- Assisted walking with harness support to maintain gait patterns
- Underwater treadmill — buoyancy supports body weight while the dog exercises rear limbs
- Range of motion exercises to prevent joint contracture
- Balance and proprioceptive exercises on unstable surfaces
- Cart/wheelchair fitting when ambulation is no longer possible, to maintain mobility and quality of life
Breed-Specific Screening Recommendations
Given the devastating and untreatable nature of DM, genetic testing serves two critical functions:
-
Breeding decisions: Eliminating the SOD1 mutation from breeding populations through selective testing and breeding. Carriers should not be bred to carriers; at-risk (homozygous) dogs should not be bred. Given the high carrier frequency in some breeds, completely eliminating carriers from breeding programs may be impractical without severely narrowing the gene pool, but avoiding carrier-to-carrier matings prevents homozygous affected offspring.
-
Clinical preparedness: Owners of genetically at-risk dogs can begin monitoring for early signs, establish baseline neurological evaluations, and have a rehabilitation plan ready to implement at the first sign of hindlimb weakness.
Research Directions
Because canine DM and human ALS share the same genetic basis, dogs with DM are invaluable translational models for ALS therapy development. Clinical trials evaluating neuroprotective agents, gene therapy, and antisense oligonucleotide approaches in DM dogs may eventually benefit both species. The University of Missouri and other veterinary neurology centers maintain active DM research programs and recruit affected dogs for clinical trials.
Limitations
The incomplete penetrance of the SOD1 mutation means that genetic test results must be interpreted carefully. A positive result indicates risk, not certainty. The absence of a definitive ante-mortem diagnostic test means that some dogs diagnosed clinically with DM may have other myelopathies with similar presentations. This diagnostic uncertainty affects the quality of clinical trial data and makes prevalence estimates imprecise.
Frequently Asked Questions
What is degenerative myelopathy and which breeds are affected?
Degenerative myelopathy is a progressive spinal cord disease caused by a mutation in the SOD1 gene. It predominantly affects German Shepherds, Pembroke Welsh Corgis, Boxers, Chesapeake Bay Retrievers, and Rhodesian Ridgebacks. The disease causes progressive hind limb weakness that advances to paralysis over 6-36 months.
Can degenerative myelopathy be prevented or cured?
There is currently no cure or treatment that halts the progression of degenerative myelopathy. However, intensive daily physiotherapy has been shown to extend the ambulatory phase by 4.6 times compared to dogs receiving no rehabilitation. Genetic testing for the SOD1 mutation allows identification of at-risk dogs and responsible breeding decisions.
How fast does degenerative myelopathy progress?
Progression varies but typically follows a predictable pattern: hind limb ataxia and weakness progressing to loss of voluntary movement in the hind limbs, then urinary and fecal incontinence, and eventually involvement of the forelimbs. Without rehabilitation, most dogs lose the ability to walk within 6-12 months of diagnosis. With intensive physiotherapy, the ambulatory phase can be extended significantly.
Should I genetically test my dog for the SOD1 mutation?
Genetic testing is recommended for breeds at elevated risk before symptoms develop and is essential for breeding dogs. However, carrying the SOD1 mutation does not guarantee disease development — many carriers never show clinical signs. The test identifies risk status (clear, carrier, at-risk) and informs both veterinary monitoring and breeding decisions.
Bottom Line
Degenerative myelopathy is a progressive, incurable spinal cord disease caused by the SOD1 mutation, but intensive daily physiotherapy extended ambulatory function by 4.6 times compared to no exercise in the strongest available study. Genetic testing identifies at-risk dogs, and aggressive rehabilitation should begin at the first sign of hindlimb weakness rather than waiting for significant function loss. DM is painless, which means quality of life can remain good for months with appropriate support, though the underlying neurodegeneration cannot be stopped.
References
- Awano T et al. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis (Proceedings of the National Academy of Sciences, 2009).
- Coates JR, Wininger FA. Canine degenerative myelopathy (Veterinary Clinics of North America: Small Animal Practice, 2010).
- Kathmann I et al. Daily controlled physiotherapy increases survival time in dogs with suspected degenerative myelopathy (Journal of Veterinary Internal Medicine, 2006).
- Zeng R et al. Breed distribution of SOD1 alleles previously associated with canine degenerative myelopathy (Journal of Veterinary Internal Medicine, 2014).